Keane, Fergus http://orcid.org/0000-0001-6651-2090
Bajwa, Raazi
Selenica, Pier
Park, Wungki http://orcid.org/0000-0002-8006-3102
Roehrl, Michael H.
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Mandelker, Diana http://orcid.org/0000-0003-4154-0567
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
Article History
Received: 13 October 2022
Accepted: 30 March 2023
First Online: 22 April 2023
Competing interests
: F.K.: No conflicts of interest to declare. R.B.: No conflicts of interest to declare. W.P.: Research Funding to MSK: Astellas, Merck (AWD-GC-260082), Gossamerbio, Miracogen. Consultin<u>g</u>: Onconics, Aegle, Cerner Enviza. PS: No conflicts of interest to declare. J.S.R.-F.: J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics and Paige.AI, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Astrazeneca, Merck, Daiichi Sankyo, Roche Tissue Diagnostics and Personalis, outside the scope of this study. M.R.: No conflicts of interest to declare. D.M.: No conflicts of interest to declare. E.O.R.: Research Funding to MSK: Genentech/Roche, Celgene/BMS, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute. Consulting/DSMB: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, Silenseed, Novartis, AstraZeneca, Noxxon, BioSapien, Cend Therapeutics, Thetis, Autem, ZielBio, Tempus, Agios (spouse), Genentech-Roche (spouse), Eisai (spouse).